Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.49 |
| ▸ | WHR1 | P49842 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.47 |
| ▸ | NSD2 | O96028 | 3/20 | 0.47 |
| ▸ | NSD3 | Q9BZ95 | 3/20 | 0.47 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320049 | 0.91 | ADRA1A (0.56) | ADRA1DADRA1AADRA1B | |
| SCHEMBL2176843 | 0.91 | EHMT2 (0.46) | EHMT2WHR1EHMT1NSD2NSD3 | |
| SCHEMBL13333093 | 0.90 | EHMT2 (0.45) | EHMT2WHR1EHMT1NSD2NSD3 | |
| SCHEMBL13333099 | 0.90 | EHMT2 (0.58) | EHMT2EHMT1NSD2NSD3DNMT3A | |
| SCHEMBL13333087 | 0.89 | EHMT2 (0.46) | EHMT2EHMT1NSD2NSD3DNMT3A | |
| SCHEMBL7919688 | 0.89 | EHMT2 (0.45) | EHMT2EHMT1NSD2NSD3DNMT3A | |
| SCHEMBL13333111 | 0.89 | EHMT2 (0.45) | EHMT2WHR1EHMT1NSD2NSD3 | |
| SCHEMBL13333095 | 0.89 | EHMT2 (0.45) | EHMT2WHR1EHMT1NSD2NSD3 | |
| SCHEMBL14715407 | 0.87 | EHMT2 (0.48) | EHMT2WHR1EHMT1NSD2NSD3 | |
| SCHEMBL2171942 | 0.87 | ADRA2A (0.48) | EHMT2WHR1EHMT1DNMT3AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216283-B | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2013-11-27 | — | — | CN | claimed |
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | claimed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | claimed |
| CN-102216283-A | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | claimed |
| EP-2346848-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | claimed |
| WO-2010054968-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | claimed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | claimed |
| CN-102216283-B | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2013-11-27 | — | — | CN | disclosed |
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| CN-102216283-A | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| EP-2346848-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
| WO-2010054968-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | EHMT2 3673/4885WHR1 4280/4885EHMT1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.